Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Medico Remedies Pvt Ltd

    Medico Remedies Pvt Ltd was incorporated in1994. It is engaged in the manufacture of tablets, capsules, dry syrups formulations at its manufacturing facility located at Palghar,

  • No Image
    Mendine Pharmaceuticals Pvt Ltd

    Mendine Pharmaceuticals Pvt Ltd was originally set up in 1932 as proprietorship firm, which was reconstituted as a Pvt Ltd company with the current name in 1975. The company ma